HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Prime Medicine (NASDAQ:PRME) and maintained a price target of $10.
October 02, 2024 | 10:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Prime Medicine and maintained a $10 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $10 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Prime Medicine's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100